Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + pegylated liposomal doxorubicin + trastuzumab
- Development stage
- Preclinical
- Lead developer
- Baxter
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), pegylated liposomal doxorubicin (an anthracycline encapsulated in a liposomal delivery system), and trastuzumab (a HER2-targeted monoclonal antibody). This combination is used for the treatment of HER2-positive breast cancer. Trastuzumab works by binding to the HER2 receptor on cancer cells, blocking cell growth and division. It targets the HER2 protein that is overexpressed in some breast cancers. Cyclophosphamide is an alkylating agent that damages DNA and prevents cancer cell replication. Pegylated liposomal doxorubicin is an anthracycline that interferes with DNA and RNA synthesis in cancer cells.
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + pegylated liposomal doxorubicin + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + pegylated liposomal doxorubicin + trastuzumab.